Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs

CONCLUSION: In comparison to bDMARDs, JAKi are associated with a slightly higher infection risk and a higher risk of herpes zoster specifically. In older patients, infection IRs are higher but similar infection risks for JAKi and bDMARDs are observed. No differences in infection risk between tofacitinib and baricitinib were found. Key Points • Compared to bDMARDs, JAKi are associated with a slightly higher infection risk for all ages • An increased risk of herpes zoster in patients who use JAK inhibitors was confirmed • No significant differences in infection incidence were found between tofacitinib and baricitinib.PMID:38703283 | DOI:10.1007/s10067-024-06980-x

Source: Herpes - May 4, 2024 Category: Infectious Diseases Authors: M A A Opdam N den Broeder B J F van den Bemt K Mulder K M van de Wiel H van Ballegooijen R van Crevel A A den Broeder Source Type: research